SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion  by Madu, Ikenna G. et al.
Virology 393 (2009) 265–271
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roSARS-coronavirus spike S2 domain ﬂanked by cysteine residues C822 and C833 is
important for activation of membrane fusion
Ikenna G. Madu, Sandrine Belouzard, Gary R. Whittaker ⁎
C4127 Veterinary Medical Center, Department of Microbiology and Immunology, Cornell University, Ithaca NY 14853, USA⁎ Corresponding author. Fax: +1 607 253 3385.
E-mail address: grw7@cornell.edu (G.R. Whittaker).
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.07.038a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 May 2009
Returned to author for revision 27 May 2009
Accepted 30 July 2009





Disulﬁde loopThe S2 domain of the coronavirus spike (S) protein is known to be responsible for mediating membrane
fusion. In addition to a well-recognized cleavage site at the S1–S2 boundary, a second proteolytic cleavage
site has been identiﬁed in the severe acute respiratory syndrome coronavirus (SARS-CoV) S2 domain (R797).
C-terminal to this S2 cleavage site is a conserved region ﬂanked by cysteine residues C822 and C833. Here,
we investigated the importance of this well conserved region for SARS-CoV S-mediated fusion activation. We
show that the residues between C822–C833 are well conserved across all coronaviruses. Mutagenic analysis
of SARS-CoV S, combined with cell–cell fusion and pseudotyped virion infectivity assays, showed a critical
role for the core-conserved residues C822, D830, L831, and C833. Based on available predictive models, we
propose that the conserved domain ﬂanked by cysteines 822 and 833 forms a loop structure that interacts
with components of the SARS-CoV S trimer to control the activation of membrane fusion.
© 2009 Elsevier Inc. All rights reserved.Introduction
The severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged in 2002 causing a global epidemic. The outbreak resulted in
about 8000 cases with a fatality of about 10% until it was quarantined
(Drosten et al., 2003; Fouchier et al., 2003). SARS-CoV still maintains a
signiﬁcant threat to human health, as novel viruses such as these still
present a possibility for re-emergence into the human population so
an understanding of the mechanics of entry is crucial in order to
develop effective treatment.
Coronaviruses are enveloped viruses with positive sense RNA
genomes that commonly cause respiratory and enteric diseaseswithin
a wide host range (Holmes, 2003). Entry of these viruses is mediated
by the viral spike glycoprotein S and a receptor on the target cell. The
viral spike glycoprotein can be cleaved into S1 and S2 domains
(Bergeron et al., 2005; Du et al., 2007; Follis et al., 2006; Huang et al.,
2006; Jackwoodet al., 2001; Kawase et al., 2009;Watanabe et al., 2008;
Yamada et al., 1998). The S1 domain of the viral spike protein dictates
tropism and is responsible for mediating receptor binding (Chen et al.,
1997; Han et al., 2007; Hensley and Baric, 1998; Hofmann et al., 2006;
Lewicki and Gallagher, 2002; Li et al., 2003, 2007; Schultze et al., 1996;
Thorp and Gallagher, 2004; Wentworth and Holmes, 2001). The S2
domain is responsible for mediating membrane fusion between the
virus and host cell, with strong sequence conservation within the
family (Bosch et al., 2004; Chu et al., 2006)—hence the mechanics of
fusion can be expected to be conserved across the Coronaviridae.ll rights reserved.Based on structural similarities, the SARS-CoV S glycoprotein is a
class 1 membrane fusion protein (Schibli and Weissenhorn, 2004).
The S2 domain contains two heptad repeat regions, HR1 and HR2, as
well as a fusion peptide. Following conformational changes based on
receptor binding or change in pH, the S2 domain drives fusion of the
viral and host cell membranes to allow virus entry. Observations of
cell surface expressed SARS-CoV spike protein, indicated that most of
the protein was not cleaved at the S1–S2 boundary and with at best
limited cleavage possible (Song et al., 2004; Xiao et al., 2003). It is
generally considered that S1–S2 cleavage is not directly linked to
fusion peptide exposure in the case of SARS-CoV, or any other
coronavirus (Bosch and Rottier, 2008). However, it has recently been
shown that SARS-CoV S can be proteolytically cleaved at a
downstream position in S2, at residue 797 (Belouzard et al., 2009),
and a highly conserved region C-terminal to the cleavage site has been
characterized and identiﬁed as critical for fusion (Madu et al., 2009).
Downstream of these conserved core residues we observed
another set of conserved residues ﬂanked by cysteines 822 and 833.
These ﬂanks represent two of the 39 cysteines in S that are likely to
form intra-disulﬁde bonds within S. Cysteine residues and their roles
in mediating entry either in the receptor binding region or in the
cytoplasmic tail have been well documented for coronaviruses (Petit
et al., 2007; Petit et al., 2005; Thorp et al., 2006; Ye et al., 2004). For
other families of viruses, cysteine residues have been key players for
driving entry (Matthias and Hogg, 2003; Matthias et al., 2002) and
fusion (Delos et al., 2008; Delos and White, 2000; Parrott et al., 2009;
Rai et al., 2004). In this study, we investigated the importance of a
conserved domain in SARS-CoV S2 ﬂanked by cysteines 822 and 833
by carrying out a comprehensive mutagenesis study. Using cell–cell
Fig. 1. Schematic and alignment of the cysteine-ﬂanked region. A schematic representation of the coronavirus spike with hallmark domains alongside the region of interest. A
multiple sequence alignment of the S protein from representative coronavirus groups was performed. Residues that are conserved directly or in terms of properties are underlined
and asterisked residues represent 100% conservation within the CoV family. Virus abbreviations and Genbank accession numbers are as follows: SARS-CoV, accession no. AAP13441;
HCoV-NL63, Human coronavirus NL63 Amsterdam accession no. AAS58177; HCoV-229E, Human coronavirus 229E accession no. AAG48592; HCoV-OC43, Human coronavirus OC43
ATCC VR-759 accession no. AAR01015; IBV, Infectious Bronchitis virus Beaudette strain accession no. AAY24433; MHV-A59, Mouse Hepatitis virus A59 accession no. AAB86819;
PEDV, Porcine epidemic diarrhea virus LZC accession no. ABM64776; Bovine CoV, Bovine coronavirus R-AH187 accession no. ABP38295; ABP87990; FIPV, Feline infectious peritonitis
virus WSU 79-1146 accession no. YP239355; TGEV, Transmissible gastroenteritis virus Purdue PUR46-MAD accession no. NP058424.
Fig. 2. Effect of point mutants on spike protein surface expression. BHK cells were
transfected with plasmids encoding wild type SARS-CoV S or alanine mutants at either
37 °C (panel A) or 32 °C (panel B). The cells were labeled with Sulfo-NHS-SS-biotin and
lysed. Lysates were afﬁnity puriﬁed with NeutraAvidin beads and resolved by SDS-
PAGE andWestern blot using anti C9 tag antibody. The biotinylation assay was repeated
three times and the results from the Western blots were quantiﬁed using IP lab
software and plotted in Sigma Plot 9.0. Error bars represent standard deviation of the
mean.
266 I.G. Madu et al. / Virology 393 (2009) 265–271fusion and pseudovirus assays, we show that this domain is critical for
the activation of SARS-CoV S-mediated membrane fusion and virus
entry.
Results
Bioinformatic analysis of the SARS-CoV S2 domain ﬂanked by cysteine
residues C822 and C833
A common feature of regions within a viral glycoprotein that are
required for entry is that they show a high degree of conservation
within a virus family. We therefore performed a multiple sequence
alignment of the spike protein of representative coronaviruses, with a
focus on the domain ﬂanked by cysteine residues C822 and C833. This
bioinformatic analysis conﬁrmed a high degree of conservation in the
region (Fig. 1). Indeed, residues C822, D830, L831, and C833 of the
SARS-CoV S represent some of the most conserved residues in that
region and across the Coronaviridae.
Cloning and expression of WT and mutant SARS-CoV S glycoproteins
To test the fusogenic properties of the conserved S2 domain
ﬂanked by cysteine residues C822 and C833 a series of mutationswere
introduced into a SARS-CoV S protein-expressing vector to generate
the following mutants: C822S, G824A, D825A, N827A, A828S, D830L,
L831D, C833S, a double cysteine mutant (C822S/C833S), a deletion of
the residues between the cysteines (Δ823–832) and a Gly-Ala-Gly
(GAG) loopmutant to replace the residues between the cysteines. The
rationale for these mutations was as follows: residues G824, D825,
N827, and A828 were simply mutated to alanine (or serine in the case
of A828) tomodify their chemical nature in an innocuousmanner; the
conserved residues C822 and C833 were mutated to serine to change
the chemical nature of the cysteines and prevent normal disulphide
bond formation; the C822S/C833S double mutant was designed to
curb the possibility of spurious disulﬁde bonding occurring with un-
paired cysteines; D830L and L831D mutants were generated to
modify the chemistry of each original residue with the corresponding
conserved residue, as both are 100% conserved; and to further address
how residues within the proposed loop might be important, we
generated a loop deletion mutant Δ823–832 and a ﬂexible tripeptide
GAG loop (Kwong et al., 1998) between the ﬂanking cysteines.In order to evaluate the effect of the mutations on the fusogenic
properties of SARS-CoV S protein, we ﬁrst veriﬁed the cell surface
expression of the mutants. The level of surface expression of the point
mutants was veriﬁed quantitatively after transfection of expression
vectors bearing mutant or wild type S protein in BHK-21 cells, at both
37 °C and 32 °C, followed by biotinylation and immunoblotting. At
37 °C, with the exception of the N827A mutant, we observed a
tolerable surface expression of many of the mutants (Fig. 2A), but at
32 °C we observed an overall better surface expression of all mutants
expressing at N65% of wild type levels (Fig. 2B) so this temperature
was used in the corresponding surface expression fusion assays as
well as in the generation of pseudotyped virions.
Fig. 4.Quantitative assays of membrane fusionmediated bymutant spike proteins. BHK
cells were cotransfected with plasmids encoding wild type SARS-CoV S or alanine
mutants and also with luciferase cDNA under the control of a T7 promoter. At 24 h post
transfection, BHK cells were then overlaid with Vero cells previously transfected with a
plasmid encoding T7 polymerase. After 3 h, fusion was induced using media containing
2 μg/ml trypsin. The cells were lysed 6 h post fusion induction and supernatants
measured for luciferase activity. Each bar is averaged from three individual repeats and
error bars represent standard deviation from the mean.
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With point mutants introduced into the viral glycoprotein, it was
important to conﬁrm that the binding to ACE2 the SARS-CoV receptor
is not altered. To conﬁrm this, we cotransfected 293T cells with a
construct expressing human ACE2 fused to the Fc-binding domain of
human IgG (hACE2-Fc) and wild type or mutant spike vectors. 48 h
post transfection, cells were lysed and afﬁnity puriﬁed for hACE2-Fc,
and then immunoblotted for SARS-CoV S to conﬁrm interactions
between receptor and spike. The levels of bindingwere observed to be
comparable, with all mutants binding ACE2 at an average of N70% of
wild type levels (Fig. 3).
Fusion assays of cells expressing WT or mutant SARS-CoV S and ACE2
With a tolerable level expression at the cell surface veriﬁed, we
were then able to evaluate how themutationsmight affect membrane
fusion. Taking advantage of trypsin as a fusion trigger for the spike
protein, we employed a quantitative method of determining SARS-
CoV S protein-mediated membrane fusion activity, by using a
luciferase-based assay system to measure cell–cell fusion. In this
assay, BHK-21 cells were cotransfectedwith wild type ormutant spike
protein along with T7 polymerase-driven luciferase gene and over-
layed with Vero E6 cells transfected with the T7 polymerase gene.
Fusion was induced by trypsin treatment, and the degree of luciferase
activity after induction of fusion was used as an indicator of the
fusogenic ability of the mutant SARS-CoV S protein, in comparison to
wild type (Fig. 4). We observed that while alanine substitution of less
conserved residues G824A, D825A, N827A, and A828S, displayed
activity close to or better than wild type, mutation of the core-
conserved residues, as well as the loop deletion and mini-loop
mutants resulted in luciferase activity that was close to background
levels in comparison to wild type activity.
Characterization of SARS-CoV S mutants in MLV-pseudotyped virions
To better understand the roles of S2 domain ﬂanked by cysteine
residues C822 and C833 in the context of a virus particle, we
employed a retrovirus-based pseudovirion system (Bartosch et al.,Fig. 3. Effect of point mutants on receptor binding. 293T cells were grown on 6 cm
dishes and cotransfected with plasmids expressing wild type or mutant spike protein
and human ACE2-Fc. The cells were lysed and the lysates were afﬁnity puriﬁed using
immobilized Protein A beads. Protein A beads were then washed and resolved via SDS-
PAGE and Western blot. The binding assay was repeated three times and results from
the Western blot quantiﬁcations were plotted using Sigma Plot 9.0 (Systat Software).2003). In this infectivity assay, 293T cells are ﬁrst cotransfected with a
murine leukemia virus (MLV) Gag-Pol and luciferase plasmid along
with either the SARS-CoV wild type or mutant S protein plasmid, or
with an empty vector control, to generate control-pseudotyped viral
particles. The transfected cells were then incubated for 72 h at 32 °C,
as this temperaturewas optimal for surface expression of themutants.
We ﬁrst conﬁrmed that a suitable level of expression of mutant spike
protein was incorporated in the viral particles, in comparison to wild
type, by blotting for spike protein in the collected supernatant 72 h
post transfection (Fig. 5). Althoughmutant N827A showed a low levelFig. 5. Incorporation of mutant spike proteins into MLV-pseudotyped virions. Spike
protein–MLV-pseudotyped virions were prepared as described in the Materials and
methods. Virions were concentrated using a 10% PEG precipitation, diluted in SDS
sample buffer, and resolved by SDS-PAGE and Western blot using a monoclonal
antibody speciﬁc for the C9 tag. The spike protein–MLV-pseudotyped virions were
generated three times for wild type or mutants, and the results from the Western blots
were quantiﬁed using IP lab software and plotted in Sigma Plot 9.0. Error bars represent
standard deviation from the mean.
Fig. 6. Infectivity of spike protein–MLV-pseudotyped virions. (A) Endosomal (non-
trypsin-mediated) infectivity of spike protein–MLV-pseudotyped virions. Virions were
bound to Vero cells at 4 °C in RPMI media for 2 h. After binding, cells were rinsed in
RPMI media before being replaced with complete DMEM and incubated at 37 °C. 48 h
post-binding cells were lysed and assayed for luciferase activity. Each bar is averaged
from three individual infectivity assays and error bars represent standard deviation of
the mean. (B) Trypsin-mediated infectivity of spike protein–MLV-pseudotyped virions.
Virions were bound to Vero cells at 4 °C in RPMI media and treated with 25 mM
ammonium chloride. Fusion was induced using serum-free media containing 2 μg/ml
trypsin. The cells were lysed 48 h post fusion induction and supernatants assayed for
luciferase activity. Each bar is averaged from three individual infectivity assays and
error bars represent standard deviation of the mean.
Fig. 7. Predicted structural model of the cysteine-ﬂanked region. (A) A three
dimensional model of the SARS-CoV S protein ectodomain trimer is shown in cartoon
form, based on PDB ﬁle 1T7G. The ﬁgure was generated in MacPyMOL (DeLano
Scientiﬁc), with the cysteine-ﬂanked region colored white, both the S1 and S2 cleavage
sites (R667 and R797) colored red and HR1 in green. (B) A monomer of the spike
depicting the environment of the cysteine-ﬂanked region. The side chains of conserved
residues C822, D830, L831 and C822 are shown.
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than 60% of the wild type the level of cell surface expression in 293T
was also conﬁrmed by our biotinylation assay (data not shown). Upon
conﬁrmation of mutant spike protein incorporation, Vero E6 cells
were then transduced with SARS-CoV S pseudovirions with compa-
rable levels of detected spike by adjusting the volume of the
supernatant to ensure that equal amounts of S protein were used in
the infectivity assay. At 48 h post transduction, cells were lysed and
luciferase activity measured as an indicator of the extent of viral
infection. The luciferase activity of the wild type was set to 100% and
luciferase activities of the mutants were normalized to wild type. As
shown in Fig. 6A, we observed a pattern that was similar to the
quantitative cell–cell fusion data (see Fig. 4) although the level
activity of the D825A mutant is at an average of about 70% of the WT.
It is considered that SARS-CoV has the ability to fuse in both
endocytic and non-endocytic compartments, and as such we assessed
any potential differences in the role of this cysteine-ﬂanked region in
each of these two pathways of virus entry. We therefore inhibited
infection by the endocytic route using the lysosomotropic base NH4Cl,
and induced fusion of surface-bound virions by trypsin activation. At
48 h post trypsin treatment, cells were assayed for luciferase activity.
We observed that in this assay of non-endosomal infection that the
overall results reﬂect both trypsin-untreated assay and the cell–cell
fusion data (Fig. 6B).
Discussion
The coronavirus spike protein is responsible for mediating both
the attachment and fusion that is required to deliver the viral genome.
Binding of the virus to the host cell receptor sets in motion a series of
rearrangements of the fusion protein in preparation for fusion. The
fusion event as directed by the S2 domain requires a concerted
cooperationwithin the domains of the fusion protein. In this study, wedescribe a conserved region essential to the S2 function of fusing host
and viral membrane.
It has been recently published that a critical cleavage event at R797
occurs in SARS-CoV S (Belouzard et al., 2009), which might expose a
viral fusion peptide (Madu et al., 2009). 25 residues C-terminal to the
cleavage site, we observed an interesting conserved domain ﬂanked
by cysteine residues C822 and C833. Given its proximity to a cleavage
site and the proposed fusion peptide, we set out to characterize this
domain. Sequence alignment of this domain showed a strong
conservation particularly in the C-terminus of the region. We set
out to carry out a series of mutagenic studies in a comprehensive
manner. Our investigation entailed the replacing of core-conserved
residues with residues to modify the chemistry of the wild type
residues, and substituting or deleting the residues between the
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C822 and C833 allowed us to gauge the extent of involvement of this
region in the membrane fusion process. In all cases, we observed very
limited to no effects on either surface expression or receptor binding,
but observed drastic loss in fusogenic ability in the mutants of the
core-conserved residues, in comparison to the wild type SARS-CoV S
in cell–cell fusion assays.
In the context of a virus particle, we generatedMLV-pseudovirions
containing either WT or mutant S proteins. The mutant proteins were
found to incorporate into MLV-pseudovirions at a level suitable for
assessment of S function during virus entry. Upon pseudoparticle
transduction, a drastic loss in the ability to infect cells was observed
for both “endosomal” and “non-endosomal” routes of infection. The
manner of sensitivity for these MLV-S mutants was very similar to the
cell–cell fusion data thus indicating the importance of this region for
fusion.
We hypothesize that this region acts as a means of relaying the
signal for fusion activationwithin the subunit of S2, presumably based
on conformational changes induced by low pH and/or receptor
binding. One possible way the domain ﬂanked by cysteine residues
C822 and C833 may do so is by forming a disulﬁde bond-anchored
loop that interacts with an as yet undisclosed part of the fusion
protein to promote membrane fusion. In the absence of a crystal
structure of the SARS-CoV S ectodomain, a predictive model of the
quaternary structure is available: PDB code 1T7G (Bernini et al., 2004;
Spiga et al., 2003) (Fig. 7A). In the context of this model, the cysteine-
ﬂanked region is represented as a loop region with the cysteines 822
and 833 positioned directly next to each other, which we predict to
form a disulphide bond (Fig. 7B). The environment is one that might
hint at further interactions with other parts of the spike protein. Of
particular interest is the ﬁnding that residues C822, L823, G824, D825,
I826, N827 and A828 within the loop are part of a major antigenic
determinant of SARS-CoV S (residues L803–A828) capable of inducing
neutralizing antibodies (Zhang et al., 2004). In conclusion, we present
data of a critical domain of SARS-CoV S2 that is required for the
successful function of S-mediated fusion. We propose this region
functions by interactions with other domain(s) in S to activate
membrane fusion. It is important to point out that in the absence of a
“true” crystal structure, we cannot rule out the fact that this region
may function throughmany other possible roles within SARS-CoV S to
aid in membrane fusion.
Materials and methods
Cell culture
BHK-21, Vero E6 and 293T cells obtained from the American Type
Culture Collectionwere used in this study. All cells weremaintained in
Dulbecco's modiﬁed Eagle's medium (DMEM, Cellgro) containing 10%
fetal bovine serum, 100 U/ml penicillin and 10 μg/ml streptomycin
(complete DMEM).
Generation of mutant SARS-CoV spike glycoproteins
Site-directed mutagenesis was carried out on the spike protein-
expressing vector pcDNA3.1-SARS-CoV S (kindly provided by Dr.
Michael Farzan, New England Primate Research Center) via PCR, using
primers obtained from IDT technologies. Mutations were then
conﬁrmed by sequencing using an Applied Biosystems Automated
3730 DNA Analyzer at the Cornell University Life Sciences Core
Laboratories Center.
Analysis of SARS-CoV S cell surface expression
BHK-21 cells were grown on 6 well plates and transfected with
1 μg of wild type or mutant spike protein-expressing plasmids usingLipofectamine 2000 (Invitrogen) for 36 h at 32 °C. Transfected cells
were washed twice with cold phosphate buffered saline (PBS) and
then labeled with 250 μg/ml Sulfo-NHS-SS-biotin (Pierce) for 30 min
on ice. 50 mM cold glycine solution was added to the cells three times
at 5 min intervals to quench unlabelled free biotin followed by a PBS
wash. The cells were lysed in 500 μl of lysis buffer (Tris-buffered saline
(TBS) containing 1% NP-40 and complete protease inhibitor mixture
(Roche Applied Science)). The lysates were afﬁnity puriﬁed using
immobilized NeutraAvidin beads (Pierce) overnight at 4 °C. Neu-
traAvidin beads were then washed with lysis buffer followed by
addition of SDS-PAGE sample loading buffer containing 100 mM
dithiothreitol. The surface expression was analyzed by Western blot
using the anti-C9 epitope tag monoclonal antibody Rho 1D4 (National
Cell Culture Center, Minneapolis MN) and images were obtained and
quantiﬁed using a LAS-3000 mini Fuji ﬁlm imaging system and
software (Fuji Photo Film Co., Ltd.). The biotinylation assay was
repeated three times and results from the Western blot quantiﬁca-
tions were plotted using Sigma Plot 9.0 (Systat Software).
Human ACE2-Fc-binding assay
293T cells were grown on 6 cm dishes and cotransfected with 2 μg
each of wild type or mutant spike protein-expressing plasmids and
human ACE2-Fc expressing plasmids using Lipofectamine 2000
(Invitrogen) for 48 h at 32 °C. Transfected cells were washed with
cold phosphate buffered saline (PBS) and the cells were lysed in 500 μl
of lysis buffer (Tris-buffered saline (TBS) containing 1% CHAPS and
complete protease inhibitor mixture (Roche Applied Science)). The
lysates were afﬁnity puriﬁed using immobilized Protein A beads
(Pierce) overnight at 4 °C. Protein A beads were then washed three
times with 0.5% CHAPS lysis buffer followed by addition of SDS-PAGE
sample loading buffer containing 100 mM dithiothreitol. The SARS-
CoV S binding to precipitated ACE2-Fc was analyzed by Western blot
using the anti-C9 epitope tag monoclonal antibody Rho 1D4 (National
Cell Culture Center, Minneapolis MN) and images were obtained and
quantiﬁed using a LAS-3000 mini Fuji ﬁlm imaging system and
software (Fuji Photo Film Co., Ltd.). The binding assay was repeated
three times and results from the Western blot quantiﬁcations were
plotted using Sigma Plot 9.0 (Systat Software).
Quantitative cell–cell fusion assay
BHK-21 cells were grown in 24 well plates and cotransfected with
wild type or mutant spike protein-expressing plasmids and a plasmid
encoding luciferase under the control of a T7 promoter, using
Lipofectamine 2000 (Invitrogen) for 24 h at 32 °C. Vero E6 cells in a
60 mm dish were also transfected with a plasmid encoding the T7
polymerase. After 24 h the BHK-21 cells were overlaid with Vero E6
cells and incubated for 3 h. Cells were treated with serum-free media
containing 2 μg/ml trypsin to induce fusion and replaced with
complete DMEM after 30 min. At 6 h post induction, cells were lysed
and assayed for Luciferase activity using a Luciferase assay kit
(Promega) and a Glomax 20/20 luminometer (Promega) to measure
light emission.
Spike protein-pseudotyped virion production
Pseudotyped virions were generated using plasmids kindly
provided by Dr. Jean Dubuisson (Lille Pasteur Institute, France).
293T cells were cotransfected with a murine leukemia virus (MLV)-
based transfer vector encoding luciferase, a MLV Gag-Pol packaging
construct and a pcDNA3.1-SARS-CoV S plasmid encoding wild type or
mutant spike envelope glycoprotein, using Exgen 500 (Fermentas) as
recommended. After incubation for 72 h at 32 °C, supernatants were
collected and ﬁltered through a 0.45 μm pore size membrane. The
level of spike protein incorporation was conﬁrmed by polyethylene
270 I.G. Madu et al. / Virology 393 (2009) 265–271glycol (PEG) concentration, centrifugation and Western blot analysis.
600 μl of ﬁltered supernatant was mixed with 200 μl 40% PEG and
centrifuged for 30 min at 4000 rpm at 4 °C. The pellet was redissolved
in SDS-PAGE sample loading buffer containing 100 mM dithiothreitol
and blotted in the same manner as described above in the cell surface
biotinylation assay.
Spike protein-pseudotyped virion infectivity assays
Equal levels of pseudoparticles were used based on the level of
spike protein-pseudotype virions quantiﬁed by Western blot, as
described above. For a typical infection assay, spike protein-
pseudotyped virions containing wild type or mutant glycoproteins
were bound for 2 h in RPMI media containing 0.2% BSA, 20 mMHEPES
to Vero E6 cells at 4 °C. Media was exchanged for complete DMEM and
incubated for 48 h at 37 °C. The cells were then lysed and luciferase
activity measured using the same methods as the quantitative cell–
cell fusion assay. In a trypsin-mediated cell surface infectivity assay,
Vero E6 cells were ﬁrst pre-incubated with 25 mM NH4Cl for 1 h at
37 °C. Pseudotyped virions were then bound for 2 h in RPMI media
containing 0.2% BSA, 20 mM HEPES, and 25 mM NH4Cl at 4 °C. The
cells were then warmed up with the addition of pre-warmed RPMI
media containing 5 μg/ml trypsin, 0.2% BSA, 20 mM HEPES, and
25 mM ammonium chloride for 5 min at 37 °C in a water bath.
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